MedTrace Logo

Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD

NCT04913389 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-03-03

No results posted yet for this study

Summary

The purpose of this randomized, placebo-controlled double-blind trial is to evaluate efficacy of acetazolamide in preventing overt altitude-related adverse health effects (ARAHE) in lowlanders with chronic obstructive pulmonary disease (COPD) developing early signs of altitude-illness during altitude travel.

Conditions

Interventions

DRUG

Acetazolamide

Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.

DRUG

Placebo

Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine, Kyrgyz Republic

    collaborator UNKNOWN

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch · University Hospital, Zürich, Switzerland

  • Talant M Sooronbaev · National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

  • Michael Furian · University Hospital, Zürich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-08-10
Completion
2023-12-31

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913389 on ClinicalTrials.gov